“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

If 2025 had a theme for the Charlotte region's life sciences ecosystem, it was this: years of planning finally meeting their moment. From landmark facility openings to record-breaking workforce ...

WASHINGTON, DC – When billionaires are in the spotlight for their oversized influence in Washington, especially in the Trump administration, comes this news: Vivek Ramaswamy’s wealth has soared even ...

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the appointment of Maykin Ho, Ph.D., to its board of directors, and the promotions of Nathan ...

Greenlight Capital's David Einhorn has been vocal about his concerns around artificial intelligence driving overvaluation in ...

Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case for more urgently needed funding in the continent's biotech ecosystem. The ...

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...